D.E. Shaw & Co’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-68,923
| Closed | -$1.3M | – | 4305 |
|
|
2019
Q3 | $1.3M | Buy |
68,923
+14,011
| +26% | +$160K | ﹤0.01% | 2671 |
|
|
2019
Q2 | $647K | Buy |
+54,912
| New | +$665K | ﹤0.01% | 2942 |
|
|
2019
Q1 | – | Sell |
-101,993
| Closed | -$1.04M | – | 4084 |
|
|
2018
Q4 | $1.04M | Buy |
101,993
+86,390
| +554% | +$1.11M | ﹤0.01% | 2624 |
|
|
2018
Q3 | $260K | Buy |
+15,603
| New | +$282K | ﹤0.01% | 3420 |
|
|
2017
Q4 | – | Sell |
-18,038
| Closed | -$221K | – | 3837 |
|
|
2017
Q3 | $221K | Buy |
+18,038
| New | +$188K | ﹤0.01% | 3273 |
|
|
2016
Q4 | – | Sell |
-18,109
| Closed | -$593K | – | 3695 |
|
|
2016
Q3 | $593K | Buy |
+18,109
| New | +$551K | ﹤0.01% | 2700 |
|
|
2016
Q2 | – | Sell |
-77,044
| Closed | -$1.89M | – | 3625 |
|
|
2016
Q1 | $1.89M | Buy |
77,044
+63,821
| +483% | +$1.48M | ﹤0.01% | 1916 |
|
|
2015
Q4 | $437K | Sell |
13,223
-907
| -6% | -$30.7K | ﹤0.01% | 3161 |
|
|
2015
Q3 | $463K | Sell |
14,130
-3,594
| -20% | -$153K | ﹤0.01% | 3111 |
|
|
2015
Q2 | $939K | Sell |
17,724
-53,734
| -75% | -$1.95M | ﹤0.01% | 2757 |
|
|
2015
Q1 | $2.06M | Buy |
71,458
+61,648
| +628% | +$1.69M | ﹤0.01% | 1991 |
|
|
2014
Q4 | $285K | Buy |
+9,810
| New | +$176K | ﹤0.01% | 3667 |
|
D.E. Shaw & Co's ALDR Position: Q4 2019 in Review
D.E. Shaw & Co sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 68,923 shares — an estimated $1.3M sold.
D.E. Shaw & Co first reported a position in ALDR in Q4 2014 and held it in 12 quarters. The position peaked at $2.06M in Q1 2015. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- D.E. Shaw & Co reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- D.E. Shaw & Co sold 68,923 Alder Biopharmaceuticals shares in Q4 2019, an estimated $1.3M.
- D.E. Shaw & Co first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 12 quarters.
- D.E. Shaw & Co's Alder Biopharmaceuticals position peaked at $2.06M in Q1 2015.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on D.E. Shaw & Co's 13F filing for Q4 2019, filed 14 Feb 2020.